Difference between revisions of "Hypericum-citalopram"
From Psychiatrienet
| Line 3: | Line 3: | ||
| to = citalopram | | to = citalopram | ||
| stop = | | stop = | ||
| − | * | + | * '''Day 1-14:'''Gradually decrease the dosage of hypericum. |
| − | | start = | + | * '''Day 15:''' stop administration of hypericum. |
| − | * '''Day | + | | start = |
| − | * '''Day | + | * '''Day 15-30:''' a wash-out period of at least two weeks is necessary. |
| − | + | * '''Day 31:''' start citalopram 20 mg/day. | |
| info = | | info = | ||
| − | * Occurrence of the serotonin syndrome is | + | * Occurrence of the serotonin syndrome is possible without wash-out period. |
| − | * Hypericum | + | * Hypericum induces enzymes of the CYP P-450 type and P-gp. |
| + | * Hypericum probably has MAO-inhibiting properties.}} | ||
Revision as of 15:53, 13 July 2009
| ||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||
Switch medication from hypericum to citalopram.[1] [2]
Stop hypericum - Day 1-14:Gradually decrease the dosage of hypericum.
- Day 15: stop administration of hypericum.
Start citalopram- Day 15-30: a wash-out period of at least two weeks is necessary.
- Day 31: start citalopram 20 mg/day.
More information- Occurrence of the serotonin syndrome is possible without wash-out period.
- Hypericum induces enzymes of the CYP P-450 type and P-gp.
- Hypericum probably has MAO-inhibiting properties.
- ↑ Switches are based on literature references on this page and expert opinions of the authors. The authors have used pharmacokinetic and receptor affinity properties to determine the switch schedules
- ↑ Stahl, S. M. (2013). Stahl's essential psychopharmacology: Neuroscientific basis and practical applications (4th ed.). Cambridge University Press.
The editors of psychiatrienet.nl take the greatest care to provide up-to-date and accurate information on this site. Nevertheless, mistakes and omissions cannot be entirely excluded. No rights devolve from the information provided. The editors and other providers of information to this site accept no responsibility for the content of this site or for the information provided therein; neither do they accept responsibility for possible damages which may derive from the use of the information on this site or from the linked sites. The editorial board accepts no responsibility for the content of the (linked) sites, for access to them, or for the products and services on these sites, nor for the occurrence of errors, viruses, and/or disruptions in service.
